Cancer Treatment Market Research Reports & Industry Analysis
Cancer is a disease characterized by uncontrolled cell proliferation. Of the more than 100 types of cancer, lung, breast, and colorectal cancer account for nearly half of new cases per year in the United States. Lung cancer, which is highly correlated with cigarette smoking, is responsible for more deaths than any other form of cancer. Cigarette smoking and other environmental factors are associated with the majority of cancers.
With the growing incidence of cancer, a growing and aging world population and significant medical advances, there will continue to be phenomenal growth in the market for cancer diagnosis and treatment products.
Cancer Treatment Industry Research & Market Reports
-
Prostate Cancer Diagnostics
... at a CAGR of 13.3% over the analysis period 2024-2030. Preliminary, one of the segments analyzed in the report, is expected to record a 12.6% CAGR and reach US$10.0 Billion by the end of the ... Read More
-
Particle Therapy
... CAGR of 8.8% over the analysis period 2024-2030. Proton Therapy, one of the segments analyzed in the report, is expected to record a 9.2% CAGR and reach US$2.3 Billion by the end of the analysis ... Read More
-
Cancer Immunotherapy Drug Discovery Outsourcing
... Billion by 2030, growing at a CAGR of 14.0% over the analysis period 2024-2030. Monoclonal Antibodies, one of the segments analyzed in the report, is expected to record a 13.4% CAGR and reach US$1.5 Billion ... Read More
-
Uterine Cancer Therapeutics and Diagnostics
... Billion by 2030, growing at a CAGR of 4.1% over the analysis period 2024-2030. Endometrial Carcinomas, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$19.0 Billion ... Read More
-
Lung Cancer Surgery
... at a CAGR of 4.2% over the analysis period 2024-2030. Thoracotomy, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$5.8 Billion by the end of the ... Read More
-
Cancer Biological Therapy
... at a CAGR of 6.0% over the analysis period 2024-2030. Monoclonal Antibodies, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$69.9 Billion by the end of ... Read More
-
HER2 - Negative Breast Cancer
... Billion by 2030, growing at a CAGR of 6.9% over the analysis period 2024-2030. Radiation, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$8.9 Billion by ... Read More
-
Ovarian Cancer Drugs
... at a CAGR of 4.5% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$2.9 Billion by the end of ... Read More
-
Testicular Cancer Drugs
... at a CAGR of 2.7% over the analysis period 2024-2030. Seminoma Drugs, one of the segments analyzed in the report, is expected to record a 2.3% CAGR and reach US$356.0 Million by the end of ... Read More
-
Bile Duct Cancer
... at a CAGR of 5.7% over the analysis period 2024-2030. Surgical Therapy, one of the segments analyzed in the report, is expected to record a 7.2% CAGR and reach US$154.1 Million by the end of ... Read More
-
Head and Neck Cancer Diagnostics
... Billion by 2030, growing at a CAGR of 12.0% over the analysis period 2024-2030. Biopsy & Blood Tests, one of the segments analyzed in the report, is expected to record a 12.9% CAGR and reach ... Read More
-
Pituitary Cancer
... CAGR of 8.9% over the analysis period 2024-2030. Pituitary Adenoma, one of the segments analyzed in the report, is expected to record a 10.1% CAGR and reach US$485.1 Million by the end of the analysis ... Read More
-
Non-Invasive Cancer Diagnostics
... at a CAGR of 6.2% over the analysis period 2024-2030. Immunochemistry, one of the segments analyzed in the report, is expected to record a 8.1% CAGR and reach US$100.5 Billion by the end of the ... Read More
-
Non-Muscle Invasive Bladder Cancer
... 2030, growing at a CAGR of 19.5% over the analysis period 2024-2030. Immunotherapy, one of the segments analyzed in the report, is expected to record a 18.9% CAGR and reach US$4.5 Billion by the end ... Read More
-
Personalized Cancer Medicines
... at a CAGR of 10.6% over the analysis period 2024-2030. Personalized Medicine Diagnostics, one of the segments analyzed in the report, is expected to record a 12.2% CAGR and reach US$258.0 Billion by the end ... Read More
-
Oral Cancer Treatment
... at a CAGR of 3.6% over the analysis period 2024-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$1.2 Billion by the end of the ... Read More
-
Urothelial Cancer Drugs
... at a CAGR of 20.7% over the analysis period 2024-2030. Immunotherapy, one of the segments analyzed in the report, is expected to record a 20.3% CAGR and reach US$13.3 Billion by the end of the ... Read More
-
Cervical Cancer Treatment
... at a CAGR of 6.0% over the analysis period 2024-2030. Squamous Cell Carcinoma (SCC), one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$9.1 Billion by the ... Read More
-
Lung Cancer Diagnostics
... at a CAGR of 7.8% over the analysis period 2024-2030. Imaging Tests, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$2.3 Billion by the end of ... Read More
-
Chronic Myelogenous Leukemia Treatment
... 2030, growing at a CAGR of 5.3% over the analysis period 2024-2030. Disease Specific Treatment, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$3.4 Billion by ... Read More
-
Leukemia Therapeutics
... CAGR of 5.6% over the analysis period 2024-2030. Chronic Myeloid Leukemia, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$9.1 Billion by the end of the ... Read More
-
Cervical Cancer Diagnostic Testing
... 2030, growing at a CAGR of 5.1% over the analysis period 2024-2030. Pap Smear, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$5.3 Billion by the ... Read More
-
Hairy Cell Leukemia
... at a CAGR of 3.7% over the analysis period 2024-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 3.7% CAGR and reach US$148.8 Billion by the end of the ... Read More
-
Checkpoint Inhibitor Refractory Cancer
... 2030, growing at a CAGR of 7.6% over the analysis period 2024-2030. PD-1 Inhibitor Type, one of the segments analyzed in the report, is expected to record a 8.8% CAGR and reach US$33.0 Billion by ... Read More
-
Anaplastic Thyroid Cancer Drugs
... 2030, growing at a CAGR of 5.9% over the analysis period 2024-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$912.1 Million by the end ... Read More
Research Assistance
